| A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. | |
| | |
MedLine Citation:
|
PMID: 21365752 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Multiple myeloma (MM) is a heterogeneous group of disorders both genotypically and phenotypically. Response to thalidomide-based induction therapy in newly diagnosed patients varies significantly in published clinical trials. Proteomic analysis was performed on 39 newly diagnosed MM patients treated with a thalidomide-based regimen (22 responders; 17 non-responders) using immunodepletion, 2-D DIGE analysis and mass spectrometry. Zinc-α-2-glycoprotein (ZAG), vitamin D-binding protein (VDB), serum amyloid-A protein (SAA) and β-2-microglobulin (B2M) had statistically significant higher concentrations in non-responders compared to responders, while haptoglobin (Hp) had a lower concentration. ELISAs were used to validate the candidate protein biomarkers using unfractionated serum from 51 newly diagnosed MM patients (29 responders; 22 non-responders). Using logistic regression, the best possible area under the curve (AUC) was 0.96 using ZAG, VDB and SAA in combination. Leave-one-out-cross-validation (LOOCV) indicated an overall predictive accuracy of 84% with associated sensitivity and specificity values of 81.8 and 86.2%, respectively. Subsequently, 16 of 22 thalidomide-refractory patients successfully achieved complete response or very good partial response using second-line treatment suggesting that the biomarker profile is specific to thalidomide response rather than identifying patients with MM refractory to all therapies. Using a novel panel of predictive biomarkers, the feasibility of predicting response to thalidomide-based therapy in previously untreated MM has been demonstrated. |
| | |
Authors:
|
Rajesh Rajpal; Paul Dowling; Justine Meiller; Colin Clarke; William G Murphy; Robert O'Connor; Malcolm Kell; Constantine Mitsiades; Paul Richardson; Kenneth C Anderson; Martin Clynes; Peter O'Gorman |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-2-14 |
Journal Detail:
|
Title: Proteomics Volume: - ISSN: 1615-9861 ISO Abbreviation: - Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-3-2 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101092707 Medline TA: Proteomics Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. |
Affiliation:
|
National Institute for Cellular Biotechnology (NICB), Dublin City University, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland; Irish Blood Transfusion Services, Dublin, Ireland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Redox-regulatory mechanisms induced by oxidative stress in Brassica juncea roots monitored by 2-DE p...
Next Document: Proteomic analysis of heterosis during maize seed germination.